Use

The MPN FISH panel is indicated in the diagnosis of myeloproliferative neoplasms with eosinophilia and as a guide to therapeutic selection. Patients with BCR‑ABL, PDGFRA or PDGFRB rearrangements are responsive to tyrosine kinase inhibitors. There currently is no established TKI therapy for diseases with FGFR1 rearrangement, but some promising new therapies have been reported. If these FISH studies are negative, that does not exclude a myeloproliferative neoplasm and molecular studies for JAK2 and/or MPL mutations should also be considered in the work‑up of a possible myeloproliferative neoplasm.